Neuraxpharm and mjn-neuro Launch EPISERAS: AI Digital Solution to Predict Real-Time Epileptic Seizures

Published: 28 Nov 2025

Author: Precedence Research

Share :

Neuraxpharm Group, a European specialist company focusing on central nervous system (CNS) disorders, and mjn-neuro, a start-up based in Spain specializing in neurotechnology. They have announced the upcoming launch of EPISERAS(r), a revolutionary digital health solution that predicts epileptic seizures in real time. The groundbreaking wearable product is a new milestone in patient-centric care of individuals with drug-resistant epilepsy. It will deliver actionable insights that empower patients, caregivers, and healthcare professionals. The system comprises a mobile application that visualizes risk levels, providing patients and caregivers with important information to increase safety and reduce the risk of accidents.

The introduction of EPISERAS(r) marks the next step in Neuraxpharm's history, as the company is no longer a purely pharmaceutical-oriented entity. They provide a comprehensive solution to CNS problems, combining pharmacological interventions with advanced digital health solutions. The safety and compliance with regulations are already certified by the device's CE mark in Europe (Class IIa medical) and the UKCA approval.

The first solution of its kind is EPISERAS(r), an ambulatory and home care system that delivers unmatched control and assurance to patients in their day-to-day lives. It is used to supplement current treatments for epilepsy, providing an additional protective layer that may greatly enhance the patient's quality of life. Furthermore, the Planned launch of EPISERAS(r) in the European market will be a strategic move by Neuraxpharm to extend its portfolio into the digital health and medical device industry.

Executives’ Statements

Neuraxpharm’s CEO, Dr. Jörg-Thomas Dierks

“At Neuraxpharm, we are dedicated to improving the lives of people with CNS disorders through continuous innovation and strong partnerships. With this launch, we are taking another important step in our journey to improve the daily lives of people with epilepsy. This breakthrough embodies our commitment to digital personalized CNS care, helping patients feel safer, more in control, and better supported. By combining our deep therapeutic expertise with cutting-edge technology, we are making our vision of holistic CNS care a reality. Our goal is to expand access to effective care that enhances safety, autonomy, and long-term well-being for patients.”

David Blánquez, Chief Executive Officer and Co-Founder of mjn-neuro

“Our team has been developing this pioneering project for more than ten years, and thanks to the results obtained from several clinical studies, mjn-neuro has successfully demonstrated solid clinical evidence supporting its effectiveness. We are now focused on ensuring that patients can benefit from this innovation, which will improve their quality of life and reduce the risk of seizure-related accidents. Working with Neuraxpharm on the European market launch is a key step in bringing this breakthrough solution to those who need it most.”